酒石酸布托啡诺、盐酸曲马多及昂丹司琼注射剂体外配伍稳定性考察
|
摘要
目的:考察酒石酸布托啡诺注射液、盐酸曲马多注射液及盐酸昂丹司琼注射液在0.9%氯化钠注射液中的配伍稳定性。方法:采用HPLC法测定配伍液中三种药物含量,考察三种药物在0.9%氯化钠注射液中,室温条件下72 h内的含量变化,同时观察与检测外观与pH变化。结果:酒石酸布托啡诺注射液、盐酸曲马多注射液及盐酸昂丹司琼注射液的配伍液在72 h内三种药物含量未见明显变化,配伍液外观澄清,pH值保持稳定。结论:酒石酸布托啡诺、盐酸曲马多及盐酸昂丹司琼在0.9%氯化钠注射液中室温条件下、72 h内保持稳定。
Objective:To investigate the compatible stability of butorphanol tartrate,tramadol hydrochloride and ondansetron hydrochloride in 0.9% sodium chloride injection.Methods:HPLC method was adopted to determine the content of 3 drugs in the compatibility solution.The content changes of 3 injections in 0.9% sodium chloride injection at room temperature for 72 hours were investigated,and changes of appearance and pH values were observed and tested.Results:The compatibility of butofenol injection,tramadol hydrochloride injection and ondansetron hydrochloride injection did not change significantly in the content of 3 drugs within 72 hours.The appearance of the compatibility solution was clarified and the pH values remained stable.Conclusion:Butorphanol tartrate injection,tramadol hydrochloride injection and ondansetron hydrochloride injection were stable in 0.9% sodium chloride injection at room temperature for 72 h.
Objective:To investigate the compatible stability of butorphanol tartrate,tramadol hydrochloride and ondansetron hydrochloride in 0.9% sodium chloride injection.Methods:HPLC method was adopted to determine the content of 3 drugs in the compatibility solution.The content changes of 3 injections in 0.9% sodium chloride injection at room temperature for 72 hours were investigated,and changes of appearance and pH values were observed and tested.Results:The compatibility of butofenol injection,tramadol hydrochloride injection and ondansetron hydrochloride injection did not change significantly in the content of 3 drugs within 72 hours.The appearance of the compatibility solution was clarified and the pH values remained stable.Conclusion:Butorphanol tartrate injection,tramadol hydrochloride injection and ondansetron hydrochloride injection were stable in 0.9% sodium chloride injection at room temperature for 72 h.
引文
[1]黄宇光,黄文起,李刚,等.酒石酸布托啡诺镇痛专家共识[J].临床麻醉学杂志,2011,27(10):1028-1029.
[2]陈富超,方宝霞,李鹏,等.酒石酸布托啡诺联合用药用于术后自控镇痛的研究进展[J].实用药物与临床,2013,16(8):734-736.
[3]陈富超,马光银,刘慧敏,等.曲马多联合布托啡诺术后静脉自控镇痛的meta分析[J].职业与健康,2013,29(18):2294-2297.
[4]李熙雯.布托啡诺与曲马多联合用于剖宫产术后静脉自控镇痛[J].江西医药,2011,46(2):171-172.
[5]郭建荣.急性疼痛治疗发展趋势-多模式镇痛[J].现代实用医学,2010,22(2):129-135.
[6]方宝霞,陈富超,李鹏,等.氯诺昔康静脉联合用药在术后镇痛中的应用及评价[J].中国医院用药评价与分析杂志,2011,11(8):684-686.
[7]徐帆.注射剂配伍稳定性研究方法学分析与评价[J].中国医院药学杂志,2009,26(10):1136-1137.
[8]陈剑,刘才堂,郭耀军,等.布托啡诺复合曲马多用于开胸术后患者自控镇痛的临床观察[J].中国医药指南,2009,7(18):70-71.
[9]黄芳,程平瑞,彭惠华,等.布托啡诺复合曲马多用于乳腺癌术后静脉自控镇痛的临床研究[J].岭南现代临床外科,2007,7(5):358-359.
[10]程平瑞,董静毅,黄雁,等.布托啡诺配伍曲马多用于腰椎手术后静脉自控镇痛的可行性[J].中国临床实用医学,2007,1(4):44-45.
[11]李鹏,陈富超,方宝霞,等.硫酸镁与酒石酸布托啡诺在0.9%氯化钠注射液中的配伍稳定性[J].医药导报,2013,32(3):392-394.
[12]方宝霞,朱军,陈富超,等.酒石酸布托啡诺与氯诺昔康在静脉镇痛泵中的配伍稳定性研究[J].中南药学,2013,11(10):732-735.
[13]陈富超,方宝霞,李鹏,等.酒石酸布托啡诺注射液在氯化钠注射液中的稳定性考察[J].中国药师,2012,15(11):1618-1620.
[14]王坚,方宝霞,陈富超,等.盐酸曲马多注射液与甲磺酸罗哌卡因注射液配伍的稳定性考察[J].中南药学,2013,11(8):580-582.
[15]于琳,陈富超,李鹏,等.盐酸曲马多注射液与氟哌利多注射液配伍的稳定性研究[J].中国药师,2013,16(8):1177-1179.
[16]张滔,方宝霞,陈富超,等.盐酸曲马多注射液与盐酸布比卡因注射液在镇痛泵中的稳定性研究[J].中国医药,2013,8(7):1011-1012.
[17]阮嫔,方宝霞,彭林,等.盐酸曲马多与盐酸甲氧氯普胺在静脉镇痛泵中的稳定性考察[J].儿科药学杂志,2014,20(3):35-38.
[18]方宝霞,陈富超,李春雷,等.盐酸曲马多与枸橼酸芬太尼在氯化钠注射液中的稳定性研究[J].药学实践杂志,2014,32(5):348-351.
[19]方宝霞,陈富超,时晓亚,等.盐酸曲马多注射液与注射用氯诺昔康在0.9%氯化钠注射液中稳定性考察[J].现代中西医结合杂志,2012,21(33):3723-3725.
[20]方宝霞,陈富超,杨兴明,等.布托啡诺、盐酸曲马多及氟哌利多注射剂在0.9%氯化钠注射液中配伍的稳定性研究[J].儿科药学杂志,2015,21(10):40-43.
[2]陈富超,方宝霞,李鹏,等.酒石酸布托啡诺联合用药用于术后自控镇痛的研究进展[J].实用药物与临床,2013,16(8):734-736.
[3]陈富超,马光银,刘慧敏,等.曲马多联合布托啡诺术后静脉自控镇痛的meta分析[J].职业与健康,2013,29(18):2294-2297.
[4]李熙雯.布托啡诺与曲马多联合用于剖宫产术后静脉自控镇痛[J].江西医药,2011,46(2):171-172.
[5]郭建荣.急性疼痛治疗发展趋势-多模式镇痛[J].现代实用医学,2010,22(2):129-135.
[6]方宝霞,陈富超,李鹏,等.氯诺昔康静脉联合用药在术后镇痛中的应用及评价[J].中国医院用药评价与分析杂志,2011,11(8):684-686.
[7]徐帆.注射剂配伍稳定性研究方法学分析与评价[J].中国医院药学杂志,2009,26(10):1136-1137.
[8]陈剑,刘才堂,郭耀军,等.布托啡诺复合曲马多用于开胸术后患者自控镇痛的临床观察[J].中国医药指南,2009,7(18):70-71.
[9]黄芳,程平瑞,彭惠华,等.布托啡诺复合曲马多用于乳腺癌术后静脉自控镇痛的临床研究[J].岭南现代临床外科,2007,7(5):358-359.
[10]程平瑞,董静毅,黄雁,等.布托啡诺配伍曲马多用于腰椎手术后静脉自控镇痛的可行性[J].中国临床实用医学,2007,1(4):44-45.
[11]李鹏,陈富超,方宝霞,等.硫酸镁与酒石酸布托啡诺在0.9%氯化钠注射液中的配伍稳定性[J].医药导报,2013,32(3):392-394.
[12]方宝霞,朱军,陈富超,等.酒石酸布托啡诺与氯诺昔康在静脉镇痛泵中的配伍稳定性研究[J].中南药学,2013,11(10):732-735.
[13]陈富超,方宝霞,李鹏,等.酒石酸布托啡诺注射液在氯化钠注射液中的稳定性考察[J].中国药师,2012,15(11):1618-1620.
[14]王坚,方宝霞,陈富超,等.盐酸曲马多注射液与甲磺酸罗哌卡因注射液配伍的稳定性考察[J].中南药学,2013,11(8):580-582.
[15]于琳,陈富超,李鹏,等.盐酸曲马多注射液与氟哌利多注射液配伍的稳定性研究[J].中国药师,2013,16(8):1177-1179.
[16]张滔,方宝霞,陈富超,等.盐酸曲马多注射液与盐酸布比卡因注射液在镇痛泵中的稳定性研究[J].中国医药,2013,8(7):1011-1012.
[17]阮嫔,方宝霞,彭林,等.盐酸曲马多与盐酸甲氧氯普胺在静脉镇痛泵中的稳定性考察[J].儿科药学杂志,2014,20(3):35-38.
[18]方宝霞,陈富超,李春雷,等.盐酸曲马多与枸橼酸芬太尼在氯化钠注射液中的稳定性研究[J].药学实践杂志,2014,32(5):348-351.
[19]方宝霞,陈富超,时晓亚,等.盐酸曲马多注射液与注射用氯诺昔康在0.9%氯化钠注射液中稳定性考察[J].现代中西医结合杂志,2012,21(33):3723-3725.
[20]方宝霞,陈富超,杨兴明,等.布托啡诺、盐酸曲马多及氟哌利多注射剂在0.9%氯化钠注射液中配伍的稳定性研究[J].儿科药学杂志,2015,21(10):40-43.